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sis. The major function of Fas-L in mature T and B lym-Laboratory of Immunology
phocytes appears to be apoptosis induction. Profes-National Institutes of Allergy and Infectious Diseases
sional APCs such as dendritic cells (DCs) utilize anotherNational Institutes of Health
TNF-like cytokine called TRAIL for apoptosis induction,Bethesda, Maryland 20892
which may limit their ability to activate lymphocytes
(Wang et al., 1999).
TNFa binds to two distinct, type I membrane receptors
One of the hallmarks of the immune system is the con- on the cell surface, TNFR-1 (p55/p60) and TNFR-2 (p75/
stant expansion and contraction of different cell popula- p80), while Fas-L binds to another TNFR-like molecule
tions as a result of homeostatic immune regulation. called Fas/CD95/Apo-1. The extracellular domains
Expansion and proliferation of T and B lymphocytes and (ECDs) of the TNFRs contain one to six characteristic
antigen-presenting cells (APCs) in the midst of antigenic cysteine-rich domains (CRDs). They can be further di-
challenges is countered by contraction of the same pop- vided into two subgroups based on the structure of
ulations of cells through apoptosis as the immune reac- their cytoplasmic tails. TNFR-1 and Fas/CD95/Apo-1 are
tion attenuates. Hence, apoptosis or programmed cell representatives of a subset of TNFR-like receptors that
death is at the heart of homeostatic balance within the share a homologous motif in the cytoplasmic tail called
immune system. Members of the tumor necrosis factor the “death domain” (DD). Upon activation, the DD serves
(TNF) receptor superfamily play critical roles in lympho- as a docking site for DD-containing adaptor proteins
cyte apoptosis during immune regulation. We will focus such as TRADD (for TNFR-1) and FADD (for Fas) through
our discussion on how structural features of TNF recep- homotypic DD interactions. Ultimately, the recruitment
tor (TNFR)-like receptors affect the regulation of T cell of caspase-8 or -10 via FADD initiates the enzymatic
homeostasis. cascade of apoptosis. Consistently, FADD or caspase-8
deficiencies lead to resistance of apoptosis induction
by Fas and TNFR-1. For the TNFR-1 signaling complex,Apoptosis in Central and Peripheral Tolerance
In the thymus, the developing T cell repertoire under- receptor activation can also lead to the recruitment of
RIP and TRAF2 through TRADD (Figure 1B). RIP is agoes positive and negative selection to achieve effec-
tiveness against foreign antigenic challenge and to DD-containing kinase that is crucial for NF-kB activation
while TRAF2 activates the MAP kinases. Both RIP orminimize the possibility of reaction to self-antigens. Evi-
dence indicates that most thymocytes do not employ TRAF2 deficiencies result in hypersensitivity to TNFa-
induced cytotoxicity (reviewed in Wallach et al., 1999).TNFR-like receptors in death induction. Mature T cells
are subject to further safeguard mechanisms in the pe- Thus, distinct adaptor proteins endow the receptors
with the ability to promote activation/inflammatory re-riphery to protect the organism from the adverse effects
of over-reaction to self- or non-self antigens. For in- sponses as well as apoptosis.
The second subgroup, which includes most of TNFR-stance, activated T cells undergo apoptosis when cyto-
kines are withdrawn, at the end of a successful immune like receptors, lacks cytoplasmic DDs but contains a
consensus motif that allows binding to the TRAF pro-response, to eliminate activated, cytokine-secreting T
cells. At the other end of the spectrum, propriocidal teins (Ye et al., 1999). To date, six TRAF proteins have
been shown to be recruited by non-DD, TNFR-like re-death is a form of feedback regulation that eradicates
T cells that are stimulated repeatedly, either by high ceptors. For TNFR-2, stimulation of the receptor results
in recruitment of TRAF1, TRAF2, and the “inhibitor oflevels of exogenous antigens or by self-antigens (Figure
1A). The death cytokines Fas ligand (Fas-L) and TNFa apoptosis proteins”, c-IAP1 and c-IAP2. The TRAF1/
TRAF2/c-IAP1/c-IAP2 complex can also be recruited toand their respective death receptors are critical media-
tors of active apoptosis in the propriocidal pathway. the TNFR-1 signaling complex and may confer antiapo-
ptotic functions (Wang et al., 1998).Although mechanistically distinct, both active and pas-
sive apoptosis are critical for the maintenance of homeo-
stasis in the mature peripheral T cell compartment. TNFRs and Fas in the Maintenance
of T Cell Homeostasis
Ligands and Receptors of the TNF Superfamily The importance of Fas and Fas-L in the maintenance
Mediate Apoptosis in the Immune System of mature T cell homeostasis is highlighted by genetic
Both TNFa and Fas-L are members of a structurally abnormalities in mice and humans. The lpr and gld mice
homologous family of cytokines whose functions are harbor mutations in the Fas and Fas-L genes, respec-
critical for the immune system. TNF-like cytokines are tively, which give rise to massive lymphadenopathy,
trimeric, type II membrane proteins that can be cleaved splenomegaly, autoimmune abnormalities, and the ac-
off the membrane by metalloproteinases. The crystal cumulation of a unique population of CD4–82 “double
structure of TNFa reveals a trimer assuming a “jelly roll” negative” (DN) T cells in the periphery. Human patients
conformation of b strands that appears to be conserved with mutations in Fas, Fas-L, and caspase-10 manifest
a phenotypically similar disease called the “Autoimmune
Lymphoproliferative Syndrome” (ALPS) (reviewed in* To whom correspondence should be addressed (e-mail: mlenardo@
nih.gov). Lenardo et al., 1999). TNFa has also been shown to
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Figure 1. TNFR Signaling and T Cell Homeo-
stasis
(A) Propriocidal and lymphokine-withdrawal
death in T cell homeostasis. Antigen (Ag)-acti-
vated T cells are driven into cell cycle by cyto-
kines like IL-2. Restimulation of the same Tcells
by antigen leads to propriocidal apoptosis
mediated by death cytokines. Removal of an-
tigen stimulation results in death receptor-
independent, lymphokine withdrawal death.
(B) Proximal components of the Fas, TNFR-1,
and TNFR-2 signal transduction pathways.
induce apoptosis in mature T lymphocytes. Surprisingly, to three symmetry of the ligand-receptor complex (Ban-
ner et al., 1993). The trimeric ligand makes contactsthis effect is principally mediated by the non-DD recep-
tor TNFR-2 rather than TNFR-1. Unlike the lpr and gld within the CRD2-3 region of the receptor and interdigi-
tates between the ECDs of the receptor chains. Recentmice, however, TNFa- and TNFR-2-deficient mice do
not develop lpr or gld-like diseases, perhaps because evidence, however, suggests that the TNFR complexes
are preassembled on the cell surface in the absence ofTNFa-mediated death affects mainly the CD81 compart-
ment and CD81 T cell expansion may be limited if CD41 ligand and that ligand binding induces a change in the
orientation of receptor chains within the complex toT cell help is normally regulated.
How does TNFR-2 initiate apoptosis? It has been pos- facilitate signal transduction (Papoff et al., 1999; Chan
et al., 2000; Siegel et al., 2000). A domain at the NH2tulated that TNFR-2 may enhance TNFR-1-induced death
by trapping TNF on the cell surface and then passing it terminal of TNFR-1, TNFR-2, and Fas overlapping CRD1
termed the PLAD (for pre-ligand binding assembly do-onto TNFR-1. This “ligand-passing” model, however,
fails to account for the critical role of intracytoplasmic main) is necessary and sufficient to mediate formation
of ligand-independent complexes (Figure 2A). The as-signaling by TNFR-2 in enhancing TNFR-1-mediated
apoptosis. TNFR-2 may skew the signal of TNFR-1 to- sembly of pre-ligand receptor complexes through the
PLAD is receptor specific, allowing only homotypic, butward death by degradation of TRAF2 and switching the
recruitment of the antiapoptotic complex of TRAF1/ not mixed complexes. Efficient ligand binding appears
to require PLAD-dependent pre-ligand complexes, al-TRAF2/c-IAP1/c-IAP2 to FADD recruitment (Chan and
Lenardo, 2000). Moreover, membrane-anchored TNFa though the PLAD and ligand binding domain are physi-
cally distinct. Intriguingly, chemical cross-linking of cellmay preferentially activate TNFR-2 to promote apopto-
sis (reviewed in Wallach et al., 1999). surface TNFRs reveals a trimer, but unliganded TNFR-1
ECDs crystallize as dimers (Naismith et al., 1996). Thus,
the stoichiometry of the preformed receptor complexSignaling through Preformed Receptor Complexes
and whether preassembly is regulated are importantSignaling by members of the TNFR superfamily was
questions to address in the future.thought to be achieved through ligand-induced trimeri-
Signaling by preassembled TNFRs can have signifi-zation of the monomeric receptor chains. This inference
cant mechanistic ramifications. Activation of Fas, TNFR-1,is based on the crystallographic structure of the ECD
of TNFR-1 bound to LTa/TNFb, which exhibits a three and TRAIL receptors 1 and 2 (DR4 and DR5) results in the
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to the cytoplasmic adaptor and effector proteins. The
fundamental multimeric structures of the receptor sig-
naling machinery suggest that any components along
the pathway are susceptible to interference by single
allele mutations encoding proteins that can associate,
but not function normally. This explains why heterozy-
gous, cytoplasmic Fas mutations in ALPS are dominant
interfering, because even a single mutant receptor chain
can prevent the recruitment of downstream signaling
proteins within the whole trimeric complex (Martin et
al., 1999). Moreover, a subset of ALPS patients contains
mutations and/or deletions in the ECD that result in non-
ligand binding, but dominant interfering receptors. In
fact, certain of the ECD mutations involve severe trunca-
tions that leave only the PLAD intact, indicating that
PLAD-mediated receptor preassociation can causeFigure 2. Schematic Diagram of the Preligand Assembly Model of
dominant interference and disrupt receptor function.TNFR Signaling
Consistently, removal of the PLAD from Fas chains withThe open ovals represent the extracellular cysteine-rich domains
cytoplasmic mutations abolishes their dominant inter-(CRD). The filled ovals denote the silencer protein SODD, and the
ference. Hence, PLAD-mediated receptor chain associ-dotted rectangles represent the recruitment of TRADD upon TNFa
ation is a key feature of lymphocyte homeostasis involv-binding. This model assumes a stable preassembled complex com-
prised of three receptor chains. ing Fas (Siegel et al., 2000).
Other human diseases involving TNFR-like receptors
could also be linked to PLAD-mediated complexes. For
instance, the TNFR-1-associated periodic syndromerapid recruitment of downstream cytoplasmic signaling
(TRAPS) is a disease characterized by episodes of feverproteins, sometimes within seconds of ligand binding
and inflammation. Heterozygous mutations in the ECD(Wallach et al., 1999; Kischkel et al., 2000; Sprick et
of TNFR-1 that cause a shedding defect of the receptoral., 2000). A rapid reorientation of receptors within the
may account for the skewed inflammatory responses inpreformed complex could explain the kinetics of signal-
these patients (McDermott et al., 1999). ECD mutationsing and circumvent a need to find three monomeric
in the RANK receptor have also been identified in severalreceptor chains at the “right place” and in the correct
cases of familial expansile osteolysis (FEO) (Hughes etorientation. The preformed receptor complex is nonsig-
al., 2000). In addition, the myxoma virus TNFR homolognaling despite the proximity of the cytoplasmic domains,
M-T2 may inhibit TNF-induced apoptosis by complexingpossibly due to the binding of the silencer of death
with TNFRs via the PLAD, thereby allowing the virus todomain (SODD) protein or its functional homologs that
evade immune destruction (Schreiber et al., 1997). Itprevents inadvertent activation of signaling (Jiang et al.,
will be important to determine if formation of aberrant1999). Alternatively, the architecture of the preformed
receptor complexes via PLAD or the lack of PLAD-medi-receptor complex may preclude signaling until ligand is
ated association contributes to the perturbation of im-bound. Homotypic PLAD-mediated receptor associa-
mune homeostasis in these situations.tion may also serve to avoid mixed trimer formation and
mutual inhibition of signaling between receptors that
bind the same ligand. Future Possibilities
TNFR-like receptors are critical mediators of both
Preformed Complexes and Immune Regulation healthy and pathogenic immune responses. Recent
Preformed TNFR complexes appear to have important therapeutic approaches aiming at disruption of TNF-
roles in both the normal and disease states of the TNFR interactions have proven to be effective in the
immune system. Naturally occurring, soluble Fas and treatment of rheumatoid arthritis. However, current treat-
TNFRs may modulate apoptosis and control inflamma- ments with anti-TNF antibody or soluble TNFR proteins
tory responses of their transmembrane counterparts via do not discriminate between TNFR-1 and TNFR-2. The
homotypic PLAD interactions. The decoy receptors for identification of the PLAD and its role in mediating pre-
TRAIL, which lack functional DDs, may also inhibit TRAIL ligand complex formation and receptor function may be
cytotoxicity by complexing with the apoptosis-signaling exploited as a novel therapeutic target in diseases that
TRAIL receptors DR4/TRAIL-R1 and DR5/TRAIL-R2. involves TNF- and TNFR-like ligand-receptor pairs. For
Formation of these nonsignaling complexes may protect example, it is possible that a PLAD-mimicking peptide
normal, nonmalignant lymphocytes from TRAIL-induced could specifically block receptor complex formation and
death while allowing normal clearance of DCs through function. Future experiments shall help to address the
apoptosis induction. questions of how these preformed TNFR complexes
Preformed receptor complexes, while conferring many signal, their role in achieving immune homeostasis, and
functional advantages, may also be vulnerable to domi- whether they are feasible targets for intervention in spe-
nant inhibition in diseases. As alluded to above, ligand- cific diseases.
receptor interaction of TNFRs assumes a trifold symme-
try, which is conserved in the structures of TRAF2 (Park Selected Reading
et al., 1999), TRAF2-TRADD complex (Park et al., 2000;
Banner, D.W., D’Arcy, A., Janes, W., Gentz, R., Schoenfeld, H.J.,Tsao et al., 2000), and TRAF2 in association with non-DD
Broger, C., Loetscher, H., and Lesslauer, W. (1993). Cell 73, 431–445.TNFRs (Ye et al., 1999). Thus, homotrimeric assembly of
ligand-receptor pairs extends through the membrane Chan, F.K., and Lenardo, M.J. (2000). Eur. J. Immunol. 30, 652–660.
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